Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT ID: NCT04209543
Last Updated: 2025-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1570 participants
INTERVENTIONAL
2019-12-30
2024-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
NCT04090957
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
NCT02834312
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
NCT01942668
Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.
NCT00775242
Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers
NCT03075956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• Efficacy Study Part: Designed to evaluate the frequency and severity of vasomotor symptoms \[VMS\] in both hysterectomized and non-hysterectomized postmenopausal participants after treatment with E4 15 mg or 20 mg or placebo for up to 13 consecutive weeks. For endometrial protection, all non-hysterectomized participants were treated with 200 mg progesterone (P4) once daily for 14 consecutive days, after completion of the E4/placebo treatment. This part of the study consisted of 3 treatment groups.
• Safety Study Part: The Endometrial and General Safety Study Part is designed to evaluate the general safety, endometrial safety, secondary efficacy (lipid, glucose metabolism, health-related quality of life (HRQoL) and treatment satisfaction) of E4 in non-hysterectomized participants. All participants received E4 20 mg in combination with 100 mg P4 continuously for up to 53 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estetrol 15 mg - Efficacy Part
Estetrol (E4) 15 mg was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks.
Estetrol
Estetrol oral tablet: administered orally once daily
Estetrol 20 mg - Efficacy Part
Estetrol (E4) 20 mg was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks.
Estetrol
Estetrol oral tablet: administered orally once daily
Placebo - Efficacy Part
Placebo was administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks.
Placebo
Placebo oral tablet: administered orally once daily
Estetrol 20 mg + P4 100 mg - Safety Part
Estetrol (E4) 20 mg and Progesterone (P4) 100 mg was administered once daily for up to 53 weeks.
Estetrol
Estetrol oral tablet: administered orally once daily
Progesterone
Progesterone oral tablet: administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estetrol
Estetrol oral tablet: administered orally once daily
Placebo
Placebo oral tablet: administered orally once daily
Progesterone
Progesterone oral tablet: administered orally once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females, ≥ 40 up to ≤ 65 years of age at randomization;
* For hysterectomized subjects: documented hysterectomy must have occurred at least 6 weeks prior to the start of screening. Hysterectomy can be total or subtotal (i.e., cervix was not removed);
* For non-hysterectomized subjects: uterus with bi-layer endometrial thickness ≤ 4 mm on TVUS;
* For non-hysterectomized subjects: an evaluable endometrial biopsy taken during screening that reveals no abnormal results, i.e., presence of hyperplasia (simple or complex, with or without atypia), presence of carcinoma, and presence of disordered proliferative endometrium findings. The screening biopsy should have sufficient endometrial tissue for diagnosis;
* Seeking treatment for relief of VMS associated with menopause;
1. For the Efficacy Study part: at least 7 moderate to severe bothersome VMS per day or at least 50 moderate to severe bothersome VMS per week in the last 7 consecutive days during the Screening period;
2. For the Endometrial and General Safety Study part: at least 1 moderate to severe VMS per week;
* Body mass index ≥ 18.0 kg/m\^2 to ≤ 38.0 kg/m\^2;
* A mammogram that shows no sign of significant disease performed during screening or within 9 months prior to the start of screening ;
* Post-menopausal status defined as any of the following:
* For non-hysterectomized subjects:
Exclusion Criteria
* For hysterectomized subjects:
2. or at least 6 weeks post-surgical bilateral oophorectomy.
* Good physical and mental health, in the judgement of the Investigator as based on medical history, physical and gynecological examination and clinical assessments performed prior Visit 1;
* Able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions;
* Able and willing to complete trial daily paper diaries (if applicable) and questionnaires.
* History of malignancy with the exception of basal cell or squamous cell carcinoma of the skin if diagnosed more than 1 year prior to the Screening visit;
* Any clinically significant findings found by the Investigator at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer (however, simple cysts confirmed by ultrasound are allowed);
* Papanicolaou (PAP) test with atypical squamous cells undetermined significance (ASC-US) or higher (low-grade intraepithelial lesion \[LSIL\], atypical squamous cells- cannot exclude high-grade intraepithelial lesion \[HSIL\] \[ASC-H\], HSIL, dysplastic or malignant cells) in sub-totally hysterectomized and non-hysterectomized subjects . Note: ASC-US is allowed if a reflex human papilloma virus (HPV) testing is performed and is negative for high risk oncogene HPV subtypes 16 and 18;
* For non-hysterectomized subjects:
1. History or presence of uterine cancer, endometrial hyperplasia, or disordered proliferative endometrium;
2. Presence of endometrial polyps;
3. Undiagnosed vaginal bleeding or undiagnosed abnormal uterine bleeding;
4. Endometrial ablation;
5. Any uterine/endometrial abnormality that in the judgment of the investigator contraindicates the use of estrogen and/or progestin therapy. This includes presence or history of adenomyosis or significant myoma;
* Systolic blood pressure (BP) higher than 130 mmHg, diastolic BP higher than 80 mmHg during screening;
* History of venous or arterial thromboembolic disease (e.g., superficial or deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.), or first degree family history of venous thromboembolism (VTE);
* History of known acquired or congenital coagulopathy or abnormal coagulation factors, including known thrombophilia's;
* Laboratory values of fasting glucose above 125 mg/dL (\>6.94 mmol/L) and/or glycated hemoglobin above 7%18;
* Dyslipoproteinemia (LDL \>190 mg/dL \[\>4.91 mmol/L\] and/or triglycerides \>300 mg/dL \[\>3.39 mmol/L\])19;
* Subjects smoking \>15 cigarettes per day;
* Presence or history of gallbladder disease, unless cholecystectomy has been performed;
* Systemic lupus erythematosus;
* Any malabsorption disorders including gastric by-pass surgery;
* History of acute liver disease in the preceding 12 months before the start of screening or presence or history of chronic or severe liver disease \[alanine transaminase (ALT) or aspartate transaminase (AST) \>2x upper limit of normal (ULN), bilirubin \>1.5 ULN\]; or liver tumors;
* Chronic or current acute renal impairment (estimated glomerular filtration rate \<60 ml/min);
* Porphyria;
* Diagnosis or treatment of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, etc.), in the judgement of the Investigator;
* Use of estrogen/progestin containing drug(s) up to:
1. 1 week before screening start for vaginal non systemic hormonal products (rings, creams, gels);
2. 4 weeks before screening start for vaginal or transdermal estrogen or estrogen/progestin products;
3. 8 weeks before screening start for oral estrogen and/or progestin products and/or selective estrogen receptor modulator therapy;
4. 8 weeks before screening start for intrauterine progestin therapy;
5. 3 months before screening start for progestin implants or estrogen alone injectable drug therapy;
6. 6 months before screening start for estrogen pellet therapy or progestin injectable drug therapy;
* Use of androgen/dehydroepiandrosterone (DHEA) containing drugs:
1. 8 weeks before screening start for oral, topical, vaginal or transdermal androgen;
2. 6 months before screening start for implantable or injectable androgen therapy;
* Use of phytoestrogens or black cohosh for the treatment of VMS up to 2 weeks before the start of screening;
* For the women participating in the Efficacy Study part: use of prescription or over-the-counter products used for the treatment of VMS, e.g., anti-depressants: paroxetine, escitalopram, methyldopa, opioid and clonidine up to 4 weeks before the start of screening, and venlafaxine and desvenlafaxine up to 3 months before the start of screening , and not willing to stop these during their participation in the trial;
* Inadequately treated hyperthyroidism with abnormal TSH and free T4 at screening. Subjects with low or high TSH are allowed if free T4 at screening is within normal range;
* History or presence of allergy/intolerance to the investigational product or drugs of this class or any component of it, or history of drug or other allergy that, in the opinion of the Investigator contraindicates subject participation;
* History of alcohol or substance abuse (including marijuana, even if legally allowed) or dependence in the previous 12 months before the start of screening as determined by the Investigator, based on reported observations;
* Sponsor or contract research organization (CRO) employees or employees under the direct supervision of the Investigator and/or involved directly in the trial;
* Subjects with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease or current malignancies that would pose a risk to the subject in the opinion of the Investigator;
* Participation in another investigational drug clinical trial within 1 month (30 days) or having received an investigational drug within the last month (30 days) before the start of screening;
* Is judged by the Investigator to be unsuitable for any reason;
* For non-hysterectomized subjects to be included in the USA and Canada: history or presence of allergy to peanuts.
40 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON Clinical Research
INDUSTRY
Estetra
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genoma Research Group, Inc.
Miami, Florida, United States
Estetra Study Site
Miami, Florida, United States
Medical Research Center of Miami II
Miami, Florida, United States
Miami Clinical Research
Miami, Florida, United States
Estetra Study Site
Birmingham, Alabama, United States
Estetra Study Site
Mesa, Arizona, United States
Estetra Study Site
Phoenix, Arizona, United States
Precision Trials AZ, LLC
Phoenix, Arizona, United States
Noble Clinical Research
Tucson, Arizona, United States
Hope Clinical Research, LLC
Canoga Park, California, United States
Estetra Study Site
Pomona, California, United States
Clinical Trials Research
Sacramento, California, United States
Estetra Study Site
Sacramento, California, United States
Estetra Study Site
Thousand Oaks, California, United States
Estetra Study Site
West Covina, California, United States
Velocity Clinical Research
Denver, Colorado, United States
Estetra Study Site
Altamonte Springs, Florida, United States
Estetra Study Site
Coconut Creek, Florida, United States
Estetra Study Site
Hialeah, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Altus Research
Lake Worth, Florida, United States
San Marcus Research Clinic, Inc.
Miami Lakes, Florida, United States
Estetra Study Site
New Port Richey, Florida, United States
Estetra Study Site
North Miami, Florida, United States
Estetra Study Site
Ocoee, Florida, United States
Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare
Orlando, Florida, United States
Estetra Study Site
Ormond Beach, Florida, United States
Estetra Study Site
Palm Harbor, Florida, United States
Estetra Study Site
Pembroke Pines, Florida, United States
Estetra Study Site
Pinellas Park, Florida, United States
Estetra Study Site
Port Saint Lucie, Florida, United States
Physician Care Clinical Research, LLC
Sarasota, Florida, United States
Estetra Study Site
Tampa, Florida, United States
Estetra Study Site
Atlanta, Georgia, United States
Infinite Clinical Trials
Morrow, Georgia, United States
Fellows Research Alliance, Inc.
Savannah, Georgia, United States
Clinical Research Prime
Idaho Falls, Idaho, United States
Praetorian Pharmaceutical Research
Marrero, Louisiana, United States
Meridian Clinical Research
Norfolk, Nebraska, United States
Jubilee Clinical Research, Inc
Las Vegas, Nevada, United States
Excel Clinical Research
Las Vegas, Nevada, United States
Hassman Research Institute
Berlin, New Jersey, United States
Bosque Women's Care
Albuquerque, New Mexico, United States
PMG Research of Charlotte, LLC
Charlotte, North Carolina, United States
Estetra Study Site
Durham, North Carolina, United States
Estetra Study Site
Columbus, Ohio, United States
Estetra Study Site
Englewood, Ohio, United States
Estetra Study Site
Philadelphia, Pennsylvania, United States
Magnolia Ob/Gyn Research Center
Myrtle Beach, South Carolina, United States
Estetra Study Site
Chattanooga, Tennessee, United States
Cedar Health Research, LLC
Dallas, Texas, United States
Signature Gyn Services
Fort Worth, Texas, United States
Estetra Study Site
Houston, Texas, United States
Biopharma Informatic, Inc. Research Center
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Cedar Health Research LLC
Irving, Texas, United States
Estetra Study Site
Plano, Texas, United States
Estetra Study Site
San Antonio, Texas, United States
Estetra Study Site
San Antonio, Texas, United States
Estetra Study Site
San Antonio, Texas, United States
Estetra Study Site
Pleasant Grove, Utah, United States
Estetra Study Site
Norfolk, Virginia, United States
Tidewater Clinical Research Inc
Virginia Beach, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
IMA Clinical Research
Morgantown, West Virginia, United States
IDIM - Instituto de Investigaciones Metabolicas
Buenos Aires, , Argentina
Mautalen Salud e Investigacion
Buenos Aires, , Argentina
Fundacion Respirar (Centro Medico Dra. De Salvo) - Instituto Argentino de Investigaciones Clinicas (IAIC) S.R.L
Buenos Aires, , Argentina
Glenny Corp. S. A. / Bioclinica Argentina
Buenos Aires, , Argentina
Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada
Caba, , Argentina
Centro de Investigacion Medico Lanus-CIMEL
Lanús, , Argentina
Centro De Investigaciones Medicas Mar Del Plata
Mar del Plata, , Argentina
Instituto de Investigaciones Clinicas Mar del Plata
Mar del Plata, , Argentina
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, , Argentina
Centro De Medicina Reprodutiva Ltda - Clinica Origen
Belo Horizonte, , Brazil
Faculdade de Medicina de Botucatu - UNESP
Botucatu, , Brazil
Centro De Pesquisa Clinica Do Brasil
Brasília, , Brazil
IPCC-Instituto de Pesquisa Clinica de Campinas
Campinas, , Brazil
University of Campinas Medical School
Campinas, , Brazil
Centro de Oncologia de Santa Catarina Ltda / Supera Oncologia
Chapecó, , Brazil
Instituto Tropical de Medicina Reprodutiva - Clinica INTRO
Cuiabá, , Brazil
CEPEME / CERHFAC Centro De Estudos E Pesquisas Em Reproducao Humana E Fertilizacao Assistida De Curitiba Ltda
Curitiba, , Brazil
Federal University Of Ceara
Fortaleza, , Brazil
Universidade Federal Do Rio Grande Do Norte/ Maternidade Escola Januario Cicco
Natal, , Brazil
Hospital Sao Vicente de Paulo, Associacao Hospitalar Beneficente Sao Vicente de Paulo
Passo Fundo, , Brazil
Hospital de Clinicas de Porto Alegre (HCPA)
Porto Alegre, , Brazil
Nucleo de Pesquisa Clinica do Rio Grande do Sul Ltda
Porto Alegre, , Brazil
Unidade de Pesquisa Clínica - Centro de Medicina Reprodutiva
Porto Alegre, , Brazil
Hospital Sao Lucas da PUC
Porto Alegre, , Brazil
lnstituto Brasil De Pesquisa Clinica S.A (IBPCLIN)
Rio de Janeiro, , Brazil
CEMEC - Faculdade de Medicina do ABC
São Bernardo do Campo, , Brazil
CPQuali Pesquisa Clinica LTDA
São Paulo, , Brazil
CPClin- Centro de Pesquisas Clinicas Ltda./Clinica Dr. Freddy Goldberg Eliaschewitz
São Paulo, , Brazil
Hospital Perola Byington/ Centro de Referencia da Saude da Mulher
São Paulo, , Brazil
Universidade Federal De Sao Paulo (Unifesp) - Hospital Sao Paulo (Hsp)
São Paulo, , Brazil
CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda
São Paulo, , Brazil
College - Centro De Pesquisa Clinica E Servicos Medicos Ltda College - Centro De Pesquisa Clinica (Baby Center Medicina Reprodutiva)
São Paulo, , Brazil
CEDOES - Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo
Vitória, , Brazil
Santa Casa De Votuporanga-Philanthropic hospital
Votuporanga, , Brazil
Aggarwal and Associates Limited
Brampton, , Canada
DIEX Research Quebec
Québec, , Canada
Clinique Rsf Inc.
Québec, , Canada
Estetra Study Site
Québec, , Canada
Alpha Recherche Clinique
Québec, , Canada
Alpha Recherche Clinique
Québec, , Canada
Estetra Study Site
Québec, , Canada
Estetra Study Site
Sarnia, , Canada
Diex Research Sherbrooke Inc.
Sherbrooke, , Canada
Diex Recherche
Victoriaville, , Canada
Fadia El Boreky Medicine Professional Corporation
Waterloo, , Canada
Dr. Vladimir Dvorak MD, Office Of
Brno, , Czechia
Gynekologie Meda Brno
Brno, , Czechia
Gynekologie Cheb s.r.o.
Cheb, , Czechia
MUDr. Petr Sak
České Budějovice, , Czechia
Dr. Jiri Tiser MD, Office of
České Budějovice, , Czechia
GYN-Mika s.r.o.
České Budějovice, , Czechia
MUDr. Martin Stepan s.r.o.
Hradec Králové, , Czechia
Gynekologie Jihlava
Jihlava, , Czechia
MUDr. Jan Kestranek - gynekologicka ambulance
Náchod, , Czechia
Estetra Study Site
Olomouc, , Czechia
G-CENTRUM Olomouc, s.r.o.
Olomouc, , Czechia
NEUMED gynekologicka ambulance s.r.o.
Olomouc, , Czechia
Dr. Karel Buchta MD, Office of
Ostrava, , Czechia
Dr. Martina Maresova Rosenbergova MD, Office of
Pilsen, , Czechia
Gynekologicka ambulance Gyncare MUDr. Michael Svec s.r.o.
Pilsen, , Czechia
Mediva s.r.o
Prague, , Czechia
Gynekologicko-porodnicka klinika
Prague, , Czechia
Dr. Lubomir Mikulasek, MD office Of
Prague, , Czechia
Vestra Clinics
Rychnov nad Kněžnou, , Czechia
Dr. Tereza Smrhova-Kovacs MD, Office of
Tábor, , Czechia
Dr. Ivana Salamonova MD, Office of
Vysoké, , Czechia
Szent Anna Privat Surgery-Szent Anna Maganrendelo
Debrecen, , Hungary
Pecsi Tudomanyegyetem (PTE) Altalanos Orvostudomanyi Kar (AOK) - Klinikai Kozpont Szuleszeti es Nogyogyaszati Klinika
Pécs, , Hungary
Univ. of Szeged Faculty of General Medicine Albert Szent-Gyaergyi
Szeged, , Hungary
Csongrad Megyei Dr. Bugyi Istvan Korhaz
Szentes, , Hungary
Ginecologia e Fisiopatologia della Riproduzione Umana,UO Ostetricia e Ginecologia,Policlinico S.Orsola-Malpighi
Bologna, , Italy
Ospedale Pugliese
Calabria, , Italy
Universita degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi, DAI Materno Infantile, SOD Ginecologia e Ostetricia
Florence, , Italy
Azienda Ospedaliero - Universitaria Policlinico di Modena
Modena, , Italy
Universita degli Studi di Perugia - Policlinico Monteluce - Centro di Medicina Perinatale e della Riproduzione
Perugia, , Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma
Roma, , Italy
Policlinico Univ. Agostino Gemelli
Roma, , Italy
Saules Family Medicine Centre
Kaunas, , Lithuania
UAB VAKK - Dr. Kildos Klinika
Kaunas, , Lithuania
Klaipedos Miesto Poliklinika
Klaipėda, , Lithuania
Public Institution Centro Poliklinika
Vilnius, , Lithuania
UAB Seimos gydytojas
Vilnius, , Lithuania
JSC Maxmeda
Vilnius, , Lithuania
JSC Kardiolita
Vilnius, , Lithuania
Vilnius University Hospital Santaros klinikos
Vilnius, , Lithuania
Prywatna Klinika Polozniczo - Ginekologiczna Sp. Z O.O.
Bialystok, , Poland
Centrum Ginekologii Endokrynologii i Medycyny Rozrodu Artemida
Bialystok, , Poland
Osrodek Badan Klinicznych IN-VIVO
Bydgoszcz, , Poland
Przychodnia Srodmiescie Sp. z o.o.
Bydgoszcz, , Poland
Mital Site Badania Kliniczne
Elblag, , Poland
Copernicus Podmiot Leczniczy - Szpital sw. Wojciecha
Gdansk, , Poland
Centrum Medyczne Mikolowska Dr Adam Sipinski
Katowice, , Poland
Clinical Medical Research sp. z o.o.
Katowice, , Poland
NZOZ Sanas
Katowice, , Poland
Centrum Medyczne Angelius Provita
Katowice, , Poland
Pro Familia Altera Sp. z o.o.
Katowice, , Poland
NZOZ Vita Longa Sp. z o.o.
Katowice, , Poland
Gyncentrum Sp. z o.o.
Katowice, , Poland
Pratia MCM Krakow
Krakow, , Poland
Grazyna Bogutyn Medico Praktyka Lekarska
Krakow, , Poland
Salve Medica-Przychodnia
Lodz, , Poland
NZOZ Medican
Lodz, , Poland
Centrum Medyczne Chodzki
Lublin, , Poland
KO-MED Centra Kliniczne Sp. z o.o., Osrodek Badan Klinicznych w Lublinie II
Lublin, , Poland
Niepubliczny Zak¿ad Opieki Zdrowotnej PROFI-MED
Lublin, , Poland
ETYKA Osrodek Badan Klinicznych
Olsztyn, , Poland
Centrum Innowacyjnych Terapii Sp. z o.o.
Piaseczno, , Poland
IRMED Osrodek Badan Klinicznych
Piotrkow Trybunalski, , Poland
Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Spolka Komandytowa
Poznan, , Poland
Estetra Study Site
Skorzewo, , Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, , Poland
Nzoz Zieniewicz Medical
Warsaw, , Poland
Centrum Badawcze Wspolczesnej Terapii Prywatny Gabinet Lekarski Dr Anna Bochenek-Mularczyk
Warsaw, , Poland
ETG Warszawa
Warsaw, , Poland
Medical Concierge Centrum Medyczne
Warsaw, , Poland
Marek Elias Gabinety Ginekologiczne
Wroclaw, , Poland
ETG Zamosc
Zamość, , Poland
Centrul Medical Unirea Policlinica Brasov
Brasov, , Romania
Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL
Brasov, , Romania
SC Centrul Medical Unirea SRL
Bucharest, , Romania
SC Quantum Medical Center SRL
Bucharest, , Romania
Centrul Medical Euromed
Bucharest, , Romania
Spitalul Clinic Nicolae Malaxa
Bucharest, , Romania
Sana Monitoring
Bucharest, , Romania
Centrul Medical Unirea - Spitalul Baneasa
Bucharest, , Romania
Spitalul Municipal Caracal
Caracal, , Romania
Centrul Medical Unirea
Constanța, , Romania
Vitaplus Medclin SRL
Craiova, , Romania
Spitalul De Urgenta Targu Mures-Emergency University County Hospital
Târgu Mureş, , Romania
SC Centrul Medical Unirea SRL
Târgu Mureş, , Romania
Scientific Center for Family Health Problems and Human Reproduction
Irkutsk, , Russia
Krasnoyarsk State Medical University named after Prof. V.F. VoinoYasenetsky
Krasnoyarsk, , Russia
LLC Olla-Med
Moscow, , Russia
Scientific Centre Of Obsterics, Gynecology And Perinatology n.a.academican V.I.Kulakov of Federal Agency of High Tech Medical Care
Moscow, , Russia
JCS Avicenna
Novosibirsk, , Russia
Clinical diagnostic center Zdorovye
Rostov-on-Don, , Russia
Saint-Petersburg State Healthcare Institution Maternity hospital
Saint Petersburg, , Russia
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott - Center Menopause and Women's Health
Saint Petersburg, , Russia
Astarta Clinic
Saint Petersburg, , Russia
Woman's consulting center #22
Saint Petersburg, , Russia
Closed Joint Stock Company Medical Company Idk
Samara, , Russia
MCM GYNPED, s.r.o.
Dubnica nad Váhom, , Slovakia
BrenCare, s. r. o.
Poprad, , Slovakia
Diatros S.L.P
Gavà, , Spain
Instituto Palacios, Salud y Medicina de la Mujer
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario Virgen del Rocio, Hospital de la Mujer
Seville, , Spain
Accellacare - (MeDiNova Limited) - Northamptonshire
Corby, , United Kingdom
Accellacare (Previously MeDiNova) Warwickshire Quality Research Site
Coventry, , United Kingdom
CPS Research
Glasgow, , United Kingdom
Egin Research Ltd
High Wycombe, , United Kingdom
Queen Charlotte's and Chelsea Hospital - Imperial College Healthcare NHS Trust
London, , United Kingdom
Accellacare - (MeDiNova Limited) - North London
Northwood, , United Kingdom
Accellacare - South London
Orpington, , United Kingdom
Estetra Study Site
Orpington, , United Kingdom
Accellacare - (MeDiNova Limited) - East London
Romford, , United Kingdom
Accellacare - (MeDiNova Limited) - Yorkshire
Shipley, , United Kingdom
Accellacare - (MeDiNova Limited) - West London
Wokingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gaspard U, Taziaux M, Jost M, Coelingh Bennink HJT, Utian WH, Lobo RA, Foidart JM. A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause. 2023 May 1;30(5):480-489. doi: 10.1097/GME.0000000000002167. Epub 2023 Feb 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIT-Do001-C301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.